|
CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
CHAPTER TWO: INTRODUCTION
- What is Cancer?
- Biochemistry of Cancer Cells
- Carcinogen Metabolism
- Causes of Cancer Growth
- History and Growth of the Cancer Treatment Market
- Industry Structure
- Demographics and Statistics
- Description of Cancers with Available products
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Head and Neck
- Kidney
- Leukemia
- Liver
- Lung Cancer
- Lymphoma
- Melanoma
- Multiple Myeloma
- Neuroblastoma
- Ovarian Cancer
- Pancreas
- Prostate Cancer
- Stomach Cancer
CHAPTER THREE: CHEMOTHERAPY
- Alkylating Agents
- Nitrogen Mustards
- Cisplatin
- Antimetabolites
- Cytosine Arabinoside
- 5-Fluorouracil (5-FU)
- Hydroxyurea
- Mercaptopurine and Thioguanine
- Methotrexate
- Cytotoxic Antibiotics
- Actinomycin D
- Daunorubicin and Doxorubicin
- Bleomycins
- Plant Derivatives
- Etoposide and Teniposide
- Vincristine and Vinblastine
- Description of Products
- Alkalyting Agents
- Antimetabolites
- Cytotoxic Antibiotics
- Plant Derivatives
- Research and Development
- New Approvals
- Products in Development
- Market Size and Growth
- Competitive Analysis
CHAPTER FOUR: HORMONE THERAPY
- Corticosteroids
- Hormone Agonists and Antagonists
- Estrogens
- Androgens
- Antiestrogens
- Antiandrogens
- Gonadotropin-Releasing Hormone Analogues
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Description of Products
- Corticosteroids
- Hormone Agonists and Antagonists
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER FIVE: IMMUNOTHERAPY/BIOTHERAPY
- Monoclonal Antibodies
- Interleukins/Interferons
- Vaccines
- Other Biotherapy
- Antisense Oligonucleotides
- Apoptosis
- Growth Factors
- Methylation
- P53
- Ras Protein Drugs
- Regulatory Enzymes
- Description of Products
- Monoclonal Antibodies
- Interleukins/Interferons
- Vaccines
- Other Biotherapy
- Research and Development
- Awaiting Approval
- Phase III
- Phase II
- Phase I
- Market Size and Growth
- Competitive Analysis
CHAPTER SIX: RADIATION THERAPY
- Effects of Radiation
- Radioactive Isotopes
- Description of Products
- Sodium Radiophosphate
- Sodium Radioiodine
- Radiopharmaceuticals
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER SEVEN: ADJUNCTIVE THERAPIES
- Antinauseants and Antiemetics
- Biologic Response Modifiers
- Anti-Infectives
- Narcotic Analgesics
- Antidepressants
- Description of Products
- Antinauseants and Antiemetics
- Hematopoietic Growth Factors
- Cytomodulatory Agents
- Anti-infectives
- Narcotic Analgesics
- Non-Narcotic Analgesics
- Antidepressants
- Research and Development
- Market Size and Growth
- Competitive Analysis
CHAPTER EIGHT: ISSUES AND TRENDS
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Alliances Acquisitions and Licensing Agreements
- Marketing and Distribution Trends
- Immunogenicity
- Geographical Trends
- United States
- European Union
- Japan
- Lifestyle and Social Issues
- Drug Delivery Advancements
- individualized chemotherapy
- Chemotherapy and Memory Loss
- Elderly Clinical Trial Involvement
- Thalidomide Controversy
- Early Detection and Screening
- New Application for Tobacco Plant
- Future Business Strategies
CHAPTER NINE: MARKET SUMMARY AND FORECAST
- Total Market Size and Forecast
CHAPTER TEN: CORPORATE PROFILES
- Introduction
- Amgen, Inc.
- AstraZeneca plc
- Biogen IDEC, Inc.
- Bristol-Myers Squibb Company/Oncology
- Chiron Corporation
- Eli Lilly & Company
- GE Healthcare
- Genentech, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson Group
- Merck & Company, Inc.
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
- Roche
- Sanofi-Aventis
- Schering-Plough Corporation
- TAP Pharmaceutical Products, Inc.
- Theragenics Corporation
APPENDIX: COMPANY DIRECTORY
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: World Market for Cancer Therapies Revenues and Growth Rates
2002-2009
- Figure 1-1: World Cancer Therapies Market 2002-2009
CHAPTER TWO: INTRODUCTION
- Table 2-1: Viruses Associated with Cancer in Humans
- Table 2-2: Estimated and Projected World Cancer Incidence by Most Common
Types of Cancer, 2003 and 2020
- Figure 2-1: Estimated and Projected World Cancer Incidence by Most Common
Types of Cancer, 2003 and 2020
- Table 2-3: Estimated and Projected World Cancer Mortality by Most Common
Types of Cancer, 2003 and 2020
- Figure 2-2: Estimated and Projected World Cancer Mortality by Most Common
Types of Cancer, 2003 and 2020
- Table 2-4: World Population by Selected Geographical Region, 2003-2050
- Figure 2-3: World Population by Selected Geographical Region, 2003-2050
- Table 2-5: Estimated World Population by Age and Geographical Region 2003
- Figure 2-4: Estimated World Population by Age and Geographical Region,
2003
- Table 2-6: Life Expectancy at Birth by Selected Countries, 2000
- Table 2-7: United States Life Expectancy at Birth, 1990-2000, and
Projections, 2005-2010
- Figure 2-5: United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2000
- Figure 2-6: United States Estimated Person-Years of Life Lost Due to
Cancer, All Races, Both Sexes, 2000
- Table 2-8: Types of Leukemia, Incidence, Characteristics, Manifestations
- Table 2-9: Types of Primary Lung Cancer, Risk Factors
- Table 2-10: Classification of Non-Hodgkins Lymphomas
- Table 2-11: Malignant Conditions of the Skin
- Table 2-12: Estimated World Incidence and Mortality of Cancers with
Available Products (thousands)
- Figure 2-7: Estimated World Incidence and Mortality of Cancers with
Available Products
- Figure 2-8: Estimated U.S. Incidence and Mortality of Cancers with
Available Products
CHAPTER THREE: CHEMOTHERAPY
- Table 3-1: Currently Marketed Alkylating Agents (Brand Name , Generic
Name, Manufacturers, Uses)
- Table 3-2: Currently Marketed Antimetabolites
- Table 3-3: Currently Marketed Cytoxic Antibiotics
- Table 3-4: Currently Marketed Plant Derivatives
- Table 3-5: Newly Approved Chemotherapy Agents
- Table 3-6: Chemotherapy Drugs in the Pipeline
- Table 3-7: World Market for Chemotherapy Products in Cancer Revenues and
Growth Rates 2002-2009
- Figure 3-1: World Chemotherapy Market 2002-2009
- Table 3-8: Estimated Chemotherapy Products Sales by Cancer Type 2004
- Figure 3-2: Estimated Market Share of Chemotherapy Product Sales by Cancer
Type 2004
- Table 3-9: Estimated Chemotherapy Product Sales by Region 2004
- Figure 3-3: World Chemotherapy Market Share by Region 2004
- Table 3-10: Estimated Leading Suppliers Revenues and Shares of the
World Chemotherapy Market 2004
- Figure 3-4: Estimated Leading Suppliers Shares of the World
Chemotherapy Market 2004
- Table 3-11: Top Chemotherapy Products Estimated Sales and Market Share in
Cancer 2004
CHAPTER FOUR: HORMONE THERAPY
- Table 4-1: Currently Marketed Corticosteroids
- Table 4-2: Currently Marketed Hormone Agonists and Antagonists
- Table 4-3: Currently Marketed Aromatase Inhibitors
- Table 4-4: Currently Marketed Selective Estrogen Receptor Modulators
- Table 4-5: Cancer Hormone Therapy in Development
- Table 4-6: World Market for Hormone Therapy Products in Cancer Revenues
and Growth Rates 2002-2009
- Figure 4-1: World Hormone Therapy Market 2002-2009
- Table 4-7: Estimated Hormone Therapy Products Sales by Cancer Type 2004
- Figure 4-2: Estimated Market Share of Hormone Therapy Product Sales by
Cancer Type 2004
- Table 4-8: Estimated Hormone Therapy Product Sales by Region 2004
- Figure 4-3: World Hormone Therapy Market Share by Region 2004
- Table 4-9: Estimated Leading Suppliers Revenues and Shares of the World
Hormone Therapy Market 2004
- Figure 4-4: Estimated Leading Suppliers Shares of the World Hormone
Therapy Market 2004
- Table 4-10: Top Hormone Therapy Products Estimated Sales and Market Share
in Cancer 2004
CHAPTER FIVE: IMMUNOTHERAPY/BIOTHERAPY
- Table 5-1: Currently Marketed Monoclonal Antibodies
- Table 5-2: Currently Marketed Interleukins/Interferons
- Table 5-3: Currently Approved Cancer Vaccines
- Table 5-4: Other Biotherapy Currently Marketed for Cancer Treatment
- Table 5-5: Cancer Immunotherapy and Biotherapy Products in Development
- Table 5-6: World Market for Biotherapy and Immunotherapy Products in
Cancer Revenues and Growth Rates 2002-2009
- Figure 5-1: World Biotherapy and Immunotherapy Market 2002-2009
- Table 5-7: Estimated Biotherapy and Immunotherapy Products Sales by Cancer
Type 2004
- Figure 4-2: Estimated Market Share of Biotherapy and Immunotherapy Product
Sales by Cancer Type 2004
- Table 5-8: Estimated Immunotherapy/Biotherapy Product Sales by Region 2004
- Figure 5-3: World Immunotherapy/Biotherapy Market Share by Region 2004
- Table 5-9: Estimated Leading Suppliers Revenues and Shares of the World
Immunotherapy and Biotherapy Market 2004
- Figure 5-4: Estimated Leading Suppliers Shares of the World
Immunotherapy and Biotherapy Market 2004
- Table 5-10: Top Immunotherapy/Biotherapy Products Estimated Sales and
Market Share in Cancer 2004
CHAPTER SIX: RADIATION THERAPY
- Table 6-1: Currently Marketed Radiation Therapy Products
- Table 6-2: Cancer Radiation Therapy in Development
- Table 6-3: World Market for Radiation Therapy Products in Cancer Revenues
and Growth Rates 2002-2009
- Figure 6-1: World Radiation Therapy Market 2002-2009
- Table 6-4: Estimated Radiation Therapy Product Sales by Region 2004
- Figure 6-2: World Radiation Therapy Market Share by Region 2004
- Table 6-5: Estimated Leading Suppliers Revenues and Shares of the World
Radiation Therapy Market 2004
- Figure 6-3: Estimated Leading Suppliers Shares of the World Radiation
Therapy Market 2004
CHAPTER SEVEN: ADJUNCTIVE THERAPIES
- Table 7-1: Side-Effects Associated with Chemotherapy
- Table 7-2: Side-Effects Associated with Radiation Therapy
- Figure 7-1: Incidence of Emesis in Cancer Patients
- Table 7-3: Chemotherapy Agents and Level of Emetic Potential
- Figure 7-2: Incidence of Bone Marrow Suppression in Cancer Patients
- Table 7-4: Common Infection Sites
- Figure 7-3: Incidence of Infection in Cancer Patients
- Figure 7-4: Incidence of Pain in Cancer Patients
- Figure 7-5: Incidence of Depression in Cancer Patients
- Table 7-5: Currently Marketed Antinauseants and Antiemetics
- Table 7-6: Currently Marketed Biological Response Modifiers
- Table 7-7: Currently Marketed Antibiotics and Antivirals for Adjunctive
Cancer Therapy
- Table 7-8: Currently Marketed Antifungals for Adjunctive Cancer Therapy
- Table 7-9: Currently Marketed Narcotic Analgesics for Adjunctive Cancer
Therapy
- Table 7-10: Currently Marketed Non-Narcotic Analgesics for Adjunctive
Cancer Therapy
- Table 7-11: Currenlty Marketed Antidepressants for Adjunctive Cancer
Therapy
- Table 7-12: Adjunctive Cancer Therapies in Development
- Table 7-13: World Market for Adjunctive Therapy Products in Cancer
Revenues and Growth Rates 2002-2009
- Figure 7-6: World Adjunctive Cancer Therapy Market 2002-2009
- Table 7-14: Estimated Adjunctive Therapy Product Sales by Region 2004
- Figure 7-7: World Adjunctive Therapy Market Share by Region 2004
- Table 7-15: Estimated Leading Suppliers Revenues and Shares of the
Adjunctive Therapies Market 2004
- Figure 7-8: Estimated Leading Suppliers Shares of the World Adjunctive
Therapies Market 2004
- Table 7-16: Top Adjunctive Therapy Products Estimated Sales and Market
Share in Cancer 2004
CHAPTER EIGHT: ISSUES AND TRENDS
- Table 8-1: Cancer Detection Tests
- Table 8-2: Competitive Strategies of Biotech Companies
CHAPTER NINE: MARKET SUMMARY AND FORECAST
- Table 9-1: World Market for Cancer Therapies Revenues and Growth Rates
2002-2009
- Figure 9-1: World Cancer Therapies Market 2002-2009
- Table 9-2: World Market for Cancer Therapies by Type 2002-2009
- Figure 9-2: World Cancer Therapies Market Revenue Trend by Type of Therapy
2002-2009
- Figure 9-3: Make-Up of World Cancer Market by Type of Therapy 2004
- Figure 9-4: Make-Up of World Cancer Market by Type of Therapy 2009
| 
View Cart
